We validated the patterns of KRAS, EGFR and TP53 mutations across our RAGs in an independent lung adenocarcinoma cohort of 87 patients (Seoul cohort, GSE40419) (chisq test p-values, EGFR 0.0002, KRAS 0.0014, TP53 0.1) (Fig. 3e). This evidence concerns the gene KRAS and lung adenocarcinoma.